PDF(Pubmed)
Abstract：
BACKGROUND: Perineural use of dexamethasone is demonstrated to extend the analgesia duration of peripheral nerve blocks (PNB), but its optimal dose remains unclear. This systematic review and meta-analysis aims to determine the optimal dose of perineural dexamethasone in the prolongation of analgesia for PNB.
METHODS: PubMed, EMBASE, the Cochrane Central Register of Controlled Trials and Web of Science will be searched from their inception to 1 March 2023. Language will be restricted to English. Randomised controlled trials that compared the efficacy and safety of different doses of perineural dexamethasone for PNB in adult patients will be included. Retrospective studies, reviews, meta-analyses, case reports, conference abstracts, comments and studies regarding paediatric surgeries will be excluded. The duration of analgesia will be defined as the primary outcome. Secondary outcomes will include pain scores, the total analgesic requirement over 48 hours and the incidence of adverse effects. Two reviewers will independently perform the study selection, data extraction and quality assessment. RevMan V.5.3 software will be used for data analysis. The quality of evidence will be assessed using the Grading of Recommendation, Assessment, Development and Evaluation (GRADE) approach.
BACKGROUND: No ethical approval is required. The results of this study will be submitted to peer-reviewed journals.
UNASSIGNED: CRD42022385672.
METHODS: PubMed, EMBASE, the Cochrane Central Register of Controlled Trials and Web of Science will be searched from their inception to 1 March 2023. Language will be restricted to English. Randomised controlled trials that compared the efficacy and safety of different doses of perineural dexamethasone for PNB in adult patients will be included. Retrospective studies, reviews, meta-analyses, case reports, conference abstracts, comments and studies regarding paediatric surgeries will be excluded. The duration of analgesia will be defined as the primary outcome. Secondary outcomes will include pain scores, the total analgesic requirement over 48 hours and the incidence of adverse effects. Two reviewers will independently perform the study selection, data extraction and quality assessment. RevMan V.5.3 software will be used for data analysis. The quality of evidence will be assessed using the Grading of Recommendation, Assessment, Development and Evaluation (GRADE) approach.
BACKGROUND: No ethical approval is required. The results of this study will be submitted to peer-reviewed journals.
UNASSIGNED: CRD42022385672.
摘要：
背景：经证明，经神经途径使用地塞米松可延长周围神经阻滞（PNB）的镇痛持续时间，但其最佳剂量仍不清楚。本系统评价和荟萃分析旨在确定神经周地塞米松在延长PNB镇痛中的最佳剂量。
方法：PubMed，EMBASE,Cochrane中央受控试验登记册和WebofScience将从其开始至2023年3月1日进行搜索。语言将仅限于英语。将包括比较成人患者中不同剂量的神经周地塞米松对PNB的疗效和安全性的随机对照试验。回顾性研究,reviews,荟萃分析，病例报告,会议摘要，有关儿科手术的评论和研究将被排除.镇痛的持续时间将被定义为主要结果。次要结果将包括疼痛评分，超过48小时的总镇痛需求和不良反应的发生率。两名评审员将独立进行研究选择，数据提取和质量评估。使用RevManV.5.3软件进行数据分析。证据质量将使用推荐标准进行评估，评估,开发和评估(等级)方法。
背景：不需要道德批准。这项研究的结果将提交给同行评审的期刊。
■CRD42022385672。
方法：PubMed，EMBASE,Cochrane中央受控试验登记册和WebofScience将从其开始至2023年3月1日进行搜索。语言将仅限于英语。将包括比较成人患者中不同剂量的神经周地塞米松对PNB的疗效和安全性的随机对照试验。回顾性研究,reviews,荟萃分析，病例报告,会议摘要，有关儿科手术的评论和研究将被排除.镇痛的持续时间将被定义为主要结果。次要结果将包括疼痛评分，超过48小时的总镇痛需求和不良反应的发生率。两名评审员将独立进行研究选择，数据提取和质量评估。使用RevManV.5.3软件进行数据分析。证据质量将使用推荐标准进行评估，评估,开发和评估(等级)方法。
背景：不需要道德批准。这项研究的结果将提交给同行评审的期刊。
■CRD42022385672。
